You are here

Shire Signs Deal to Develop a New Way to Administer Hemophilia Drug

New technology would allow oral dosing of drugs typically administered by injection

Shire PLC is partnering with a California-based company to develop a new way to administer a drug to treat hemophilia A, according to reporting by Reuters. The company, Rani Therapeutics, has developed a technology that will help oral delivery of peptides, proteins, and therapeutic antibodies that to date could be delivered only through injections.

Once delivered through Rani Pill—the oral delivery technology—the drug stays in the body until it enters the small intestine and the medicine is transferred into the intestinal wall, the companies said. The method does not expose the medication to digestive enzymes and is also expected to be pain free, since the intestines do not have sharp pain receptors, the companies said.

Shire, which made an equity investment in Rani, has the option to negotiate a licensing deal to develop and market the drug delivery approach, after completion of certain studies.

Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.

Source: Reuters; December 5, 2017.

More Headlines

Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
New Drug Reduces Infection in Chemotherapy Patients
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes
High-Tech “Nightwatch” is Capable of Detecting 85 Percent of Severe Night-Time Epileptic Seizures
Combination of Buprenorphine and Samidorphan Targets Opioid System Safely and Effectively
Prevents Harmful Effects of Chemotherapy